Millennium Management
BEAM icon

Millennium Management’s Beam Therapeutics BEAM Stock Holding History

Millennium Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,800
Closed -$800K – 6572
2022
Q3 		$800K Buy
+16,800
New +$958K ﹤0.01% 4529

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Millennium Management's BEAM Position: Q2 2026 in Review

Millennium Management increased its Beam Therapeutics (BEAM) stake by 54% in Q2 2026, buying an estimated $363K and bringing the position to 34,260 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #4210.

Millennium Management first reported a position in BEAM in Q1 2020 and has held it in 25 quarters since. The position peaked at $33.1M in Q1 2022. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Millennium Management held 34,260 shares of Beam Therapeutics worth $1.18M as of Q2 2026.
  • Millennium Management bought 12,026 Beam Therapeutics shares in Q2 2026, an estimated $363K.
  • Beam Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #4210 holding.
  • Millennium Management first reported a position in Beam Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Millennium Management's Beam Therapeutics position peaked at $33.1M in Q1 2022.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.